A Short Perspective on the Long Road to Effective Treatments for Alzheimer's Disease

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2019 Jan 19

PMID 30657599

Citations 12

Authors

David S Reynolds

Affiliations

Soon will be listed here.

Abstract

Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease-modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease-modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.

Citing Articles

Plasma and CSF biomarkers of aging and cognitive decline in Caribbean vervets.

Varma C, Luo E, Bostrom G, Bathini P, Berdnik D, Wyss-Coray T Alzheimers Dement. 2024; 20(8):5460-5480.

PMID: 38946666 PMC: 11350037. DOI: 10.1002/alz.14038.

Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer's disease.

Qi X, Chen P, Wang Y, Zhou Z, Liu X, Fang H Transl Neurodegener. 2024; 13(1):3.

PMID: 38191451 PMC: 10773087. DOI: 10.1186/s40035-023-00394-6.

Self-healing hydrogel as an injectable implant: translation in brain diseases.

Xu J, Hsu S J Biomed Sci. 2023; 30(1):43.

PMID: 37340481 PMC: 10280980. DOI: 10.1186/s12929-023-00939-x.

The role of opioid receptors in modulating Alzheimer's Disease.

Tanguturi P, Streicher J Front Pharmacol. 2023; 14:1056402.

PMID: 36937877 PMC: 10014470. DOI: 10.3389/fphar.2023.1056402.

Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease.

Musumeci T, Di Benedetto G, Carbone C, Bonaccorso A, Amato G, Lo Faro M Biomedicines. 2022; 10(5).

PMID: 35625722 PMC: 9138905. DOI: 10.3390/biomedicines10050985.

References

Lendon C, Ashall F, Goate A . Exploring the etiology of Alzheimer disease using molecular genetics. JAMA. 1997; 277(10):825-31. View

Reiman E, Langbaum J, Tariot P, Lopera F, Bateman R, Morris J . CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2015; 12(1):56-61. PMC: 4847536. DOI: 10.1038/nrneurol.2015.177. View

Mills S, Mallmann J, Santacruz A, Fuqua A, Carril M, Aisen P . Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013; 169(10):737-43. PMC: 3880800. DOI: 10.1016/j.neurol.2013.07.017. View

Salter M, Stevens B . Microglia emerge as central players in brain disease. Nat Med. 2017; 23(9):1018-1027. DOI: 10.1038/nm.4397. View

Bursavich M, Harrison B, Blain J . Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?. J Med Chem. 2016; 59(16):7389-409. DOI: 10.1021/acs.jmedchem.5b01960. View

Amieva H, Le Goff M, Millet X, Orgogozo J, Peres K, Barberger-Gateau P . Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008; 64(5):492-8. DOI: 10.1002/ana.21509. View

Sinha S, Anderson J, Barbour R, Basi G, Caccavello R, Davis D . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999; 402(6761):537-40. DOI: 10.1038/990114. View

Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D . Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003; 60(12):1696-702. DOI: 10.1001/archneur.60.12.1696. View

10.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

11.

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

12.

Klunk W, Wang Y, Huang G, Debnath M, Holt D, Mathis C . Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001; 69(13):1471-84. DOI: 10.1016/s0024-3205(01)01232-2. View

13.

Ludewig S, Korte M . Novel Insights into the Physiological Function of the APP (Gene) Family and Its Proteolytic Fragments in Synaptic Plasticity. Front Mol Neurosci. 2017; 9:161. PMC: 5247455. DOI: 10.3389/fnmol.2016.00161. View

14.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks D . Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2011; 69(2):198-207. DOI: 10.1001/archneurol.2011.1538. View

15.

Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D . Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci. 1996; 16(18):5795-811. PMC: 6578961. View

16.

Yan R, Bienkowski M, Shuck M, Miao H, Tory M, Pauley A . Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999; 402(6761):533-7. DOI: 10.1038/990107. View

17.

Hussain I, Powell D, Howlett D, Tew D, Meek T, Chapman C . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999; 14(6):419-27. DOI: 10.1006/mcne.1999.0811. View

18.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

19.

Varley J, Brooks D, Edison P . Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimers Dement. 2014; 11(9):1110-20. DOI: 10.1016/j.jalz.2014.08.105. View

20.

Brettschneider J, Del Tredici K, Lee V, Trojanowski J . Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015; 16(2):109-20. PMC: 4312418. DOI: 10.1038/nrn3887. View